Phase 3 Clinical Trials With Primary Completion Dates in March 2019
This is a list of Phase 3 trials with primary completion dates in March 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ASND | Ascendis Pharma A/S | 2019-03-01 | Phase 3 | NCT03305016 | A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency |
| ASND | Ascendis Pharma A/S | 2019-03-01 | Phase 3 | NCT02781727 | A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD) |
| CARA | Cara Therapeutics, Inc. | 2019-03-01 | Phase 3 | NCT03422653 | A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus |
| CPRX | Catalyst Pharmaceuticals, Inc. | 2019-03-01 | Phase 3 | NCT03304054 | Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG |
| FGEN | FibroGen, Inc | 2019-03-01 | Phase 3 | NCT03263091 | Efficacy and Safety of FG-4592 for Treatment of Anemia in Patients With Lower Risk MDS With Low Red Blood Cell Transfusion Burden |
| KMPH | KemPharm, Inc. | 2019-03-01 | Phase 3 | NCT03460652 | KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD |
| NVAX | Novavax, Inc. | 2019-03-01 | Phase 3 | NCT02624947 | A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization |
| ONTX | Onconova Therapeutics, Inc. | 2019-03-01 | Phase 3 | NCT02562443 | Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA |
| SNGX | Soligenix, Inc. | 2019-03-01 | Phase 3 | NCT03237325 | DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer |
| SNY | Sanofi | 2019-03-01 | Phase 3 | NCT02926950 | Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin |
| SUPN | Supernus Pharmaceuticals, Inc. | 2019-03-01 | Phase 3 | NCT02691182 | Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4) |
| XERS | Xeris Pharmaceuticals, Inc. | 2019-03-01 | Phase 3 | NCT03738865 | G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes |
| ZSAN | Zosano Pharma Corporation | 2019-03-01 | Phase 3 | NCT03282227 | A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine |